Get the Stockscreener App
1.72
4.44%
-0.08
Pre-market:
1.72
Pliant Therapeutics Inc stock is traded at $1.72, with a volume of 434.70K.
It is down -4.44% in the last 24 hours and up +15.44% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.80
Open:
$1.77
24h Volume:
434.70K
Relative Volume:
0.54
Market Cap:
$105.59M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.5566
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+12.42%
1M Performance:
+15.44%
6M Performance:
+24.64%
1Y Performance:
-87.51%
1-Day Range:
$1.68
$1.80
1-Week Range:
$1.45
$1.815
52-Week Range:
$1.1001
$15.80
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.72 | 110.61M | 5.03M | -185.41M | -139.79M | -3.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
434.52 | 110.16B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
694.99 | 71.65B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.97 | 59.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.73 | 54.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
368.36 | 41.77B | 4.98B | 69.59M | 525.67M | 0.5197 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Why Pliant Therapeutics Inc. stock is in analyst buy zoneWeekly Gains Summary & Stepwise Trade Signal Implementation - newser.com
How rising interest rates impact Pliant Therapeutics Inc. stockJuly 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
Will Pliant Therapeutics Inc. stock deliver shareholder valueMarket Volume Report & Risk Adjusted Swing Trade Ideas - newser.com
What high frequency data says about Pliant Therapeutics Inc.2025 Fundamental Recap & Weekly High Return Forecasts - newser.com
Does Pliant Therapeutics Inc. show high probability of reboundEarnings Summary Report & Capital Efficient Trading Techniques - newser.com
Is Pliant Therapeutics Inc. stock near bottom after declineJuly 2025 Update & Technical Pattern Alert System - newser.com
Why global investors buy Pliant Therapeutics Inc. (9PT) stockMarket Performance Report & Free Long-Term Investment Growth Plans - newser.com
Chart overlay techniques for tracking Pliant Therapeutics Inc.IPO Watch & Expert Curated Trade Ideas - newser.com
Why Pliant Therapeutics Inc. (9PT) stock could be top winnerMarket Growth Review & Pattern Based Trade Signal System - newser.com
Why Pliant Therapeutics Inc. stock is favored by top institutionsWeekly Profit Recap & Reliable Volume Spike Trade Alerts - newser.com
Can Pliant Therapeutics Inc. stock maintain operating marginsJuly 2025 Gainers & Comprehensive Market Scan Reports - newser.com
What indicators show strength in Pliant Therapeutics Inc.2025 Key Highlights & Daily Profit Maximizing Trade Tips - newser.com
What analysts say about Pliant Therapeutics Inc stockMarket Breadth Indicators & Free Daily Investment Newsletter Subscription - earlytimes.in
Pliant Therapeutics (NASDAQ:PLRX) Posts Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
RBC Capital Maintains Pliant Therapeutics (PLRX) Sector Perform Recommendation - Nasdaq
Pliant Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
RBC Capital Lowers Price Target on Pliant Therapeutics (PLRX) | - GuruFocus
RBC Capital Adjusts Pliant Therapeutics Price Target to $2 From $3, Maintains Sector Perform Rating - MarketScreener
Will Pliant Therapeutics Inc. (9PT) stock outperform global peersEarnings Miss & Consistent Profit Trading Strategies - newser.com
Is Pliant Therapeutics Inc a good long term investmentTechnical Pattern Recognition & Minimal Investment Big Returns - earlytimes.in
Pliant Therapeutics Reports Improved Q3 2025 Results - The Globe and Mail
Can Pliant Therapeutics Inc. (9PT) stock double in coming yearsDip Buying & AI Enhanced Trading Alerts - newser.com
Pliant Therapeutics (PLRX) Advances Portfolio Amid Strategic Tra - GuruFocus
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results - GlobeNewswire
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):